Back to top

Latest News

mens health week
12 June 2018

Men’s Health Week 2018 – Making Health Connections

Whilst MS affects roughly three times as many women than men, recently released prevalence figures indicate that nearly 8000 men in Australia deal with MS on a daily basis. (1)

Research also indicates that the more severe and less treatable form of the condition – Primary progressive MS (...

World MS Day
28 May 2018

WORLD MS DAY 2018 – This WEDNESDAY 30th May!

Global MS Community Spotlights Research

MS Australia, MS Research Australia, the four state/territory MS organisations and the international multiple sclerosis (MS) community will recognise World MS Day this Wednesday 30th May 2018.

...

volunteers
24 May 2018

MS Australia celebrates National Volunteer Week, 21-27 May 2018

The multiple sclerosis (MS) community in Australia is supported by thousands of generous volunteers.  Without these volunteers, organisations such as MS Australia and the State/territory MS organisations couldn’t fundraise, offer services and support, or advocate to improve the lives of people...

nurse and patient
10 May 2018

International Nurses Day: Celebrating those very special specialists

This Saturday 12th May, sees us recognising International Nurses Day. It’s no coincidence that it’s also the birthday of the founder of modern nursing, Florence Nightingale.

For many of us in the MS community, this day is the perfect time to...

sour lollies
9 May 2018

Budget 2018 - A mix of sweet and sour for the MS community

MS Australia (MSA) welcomes some sweet choices for people with multiple sclerosis (MS) in the 2018-19 Australian Budget, but mixed with some sour notes too.

We make the following specific observations:


HEALTH

MSA welcomes the...

person with MS using cane
26 April 2018

A renewed call for fully funding the NDIS.

MS Australia today joins other disability peak organisations such as NDS, Every Australian Counts and PWDA, in calling for more information as to how the...

Image of white pills
20 April 2018

PBS listing for MAVENCLAD® (cladribine tablets) for RRMS not recommended by PBAC

The Pharmaceutical Benefits Advisory Committee (PBAC) announced at 4pm today (20/4/18), they have not recommended the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).

The PBAC said that it, “did not recommend the...

World MS Day 2018
19 April 2018

World MS Day 2018 - six weeks away!

Exciting news from the Multiple Sclerosis International Federation (MSIF)!

 
Overnight, MSIF launched this year’s World MS Day #bringinguscloser campaign, with the theme of Research. 
 
A highlight of the campaign is a clever animation on how new...
advance care planning week
16 April 2018

MS Australia marks Advance Care Planning Week – 16-22 April 2018

If you couldn’t speak for yourself, who would you want to speak on your behalf?

What decisions about your healthcare would you want them to make?

Planning medical care in advance regardless of your age or health is really important, and particularly so if you have a chronic illness...

Biogen image
16 March 2018

ZINBRYTA (daclizumab) voluntary withdrawal – Federal Department of Health/TGA statement

Please talk to your neurologist if you are on Zinbryta.

Further to our 5/3/18 news report on the withdrawal of ZINBRYTA (daclizumab), the Department of Health/TGA issued a statement on 15 March 2018, with extra information for the public, health professionals and neurologists...

Photo of Deidre Mackechnie
8 March 2018

MS Australia CEO, Deidre Mackechnie, celebrates International Women's Day 2018

International Women’s Day provides a worldwide focus on gender disparity.  But also gives us a day to celebrate the contribution of all women and to acknowledge the challenges faced by many.

For more than 17,000 women living in Australia that challenge is Multiple Sclerosis.

...

biogen
5 March 2018

ZINBRYTA (daclizumab) voluntary withdrawal

As reported in various media outlets over the weekend, pharmaceutical companies Biogen and AbbVie have announced the voluntary worldwide withdrawal for ZINBRYTA ® (daclizumab) for Relapsing multiple sclerosis.

As stated in the official media release (link below), patients currently...

Pages